Ann: Resignation of Janet West AM, page-21

First 21 Last

Share
Profile

Follow
austinhealey64

1,745 Posts.

240

01/11/23

10:28

Post #: 70660719
Share

Originally posted by sundowner1234: ↑

Sorry but I disagree strongly here. The lack of progress in sales for the quarter would have nothing to do with the new board. If the old board couldn't maintain their focus while facing an election then it proves they could walk and chew gum at the same time. A pretty basic task. If they could chew and walk then their sales platform is insufficient and needs tuning. Either way, a good reason for the board change. As far as share price goes, existing sales didn't support a 400M MC Simple. I was hoping we would see an extension of the trend from the previous quarter, that would have been supportive. With the drop in sales and Paridize selling we now sit at a more balanced 200M MC.

What I really want to know is who's the leaky ship that tipped of Paridize.
I did like recurring revenue starting to look a little more exponential. A couple of good sales months should see that really start to shape up.
Guidance looked a little low at first but I guess that takes in the lack of revenue from the trials. This is an avenue I would like to see pushed harder, clinical trials rather than branching into Renal to early. Priority one is cash management, Admin cost need trimming for a start. we need to get under 3M cash burn (without tax grants) and fast, then a line drawn to neutral ASAP

Expand

lol

This is what you get with board spills. Leaky ships, staff leaving, management distraction, sales slipping.

old BOD were people. People talk to people. It doesn't take much to derail sales.

Where's the money for more trials coming from? oh no another CR - this one will be at 7 cents.

This has a long time to play out yet.

IPD Price at posting: 11.0¢ Sentiment: Hold Disclosure: Held
6 Upvote

0 Great analysis

Reply